SCHEMBL9924432

SCHEMBL9924432

CCOC(=O)N[C@H]1CC[C@H](N/C(=N\C(=O)c2ccc(F)c(F)c2)NC2CCCC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
TAS1R2 Q8TE23 1/20 0.41
MAPT P10636 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MCHR1 Q99705 4/20 0.40
FAAH O00519 5/20 0.39
ALDH1A1 P00352 1/20 0.39
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38
EPHX1 P07099 1/20 0.38
CYP2C9 P11712 1/20 0.38
MAPK14 Q16539 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17206716 1.00 CHRM1 (0.43) CHRM1TAS1R3TAS1R1TAS1R2MAPT
SCHEMBL17206712 0.99 CHRM1 (0.43) CHRM1TAS1R3TAS1R1TAS1R2MAPT
SCHEMBL9924156 0.97 CHRM1 (0.45) CHRM1TAS1R3TAS1R1TAS1R2MCHR1
SCHEMBL17206707 0.93 TAS1R3 (0.43) CHRM1TAS1R3TAS1R1TAS1R2NPC1
SCHEMBL17206703 0.90 CHRM1 (0.41) CHRM1TAS1R3TAS1R1TAS1R2MCHR1
SCHEMBL9924076 0.89 CHRM1 (0.41) CHRM1TAS1R3TAS1R1TAS1R2MCHR1
SCHEMBL17206722 0.87 CHRM1 (0.41) CHRM1TAS1R3TAS1R1TAS1R2MCHR1
SCHEMBL9923856 0.87 CHRM1 (0.42) CHRM1MAPTSMN1; SMN2MCHR1ALDH1A1
SCHEMBL9924158 0.87 CHRM1 (0.42) CHRM1TAS1R3TAS1R1TAS1R2MCHR1
SCHEMBL9924154 0.86 CHRM1 (0.40) CHRM1TAS1R3TAS1R1TAS1R2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed